# US 2003/0204181 A1 · Methods and apparatus for delivering a drug influencing appetite for treatment of eating disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0204181 A1
- Document ID: US20030204181A1
- Status: Published application
- Kind: A1
- Application number: 10/133,251
- Filed: 2002-04-26
- Published: 2003-10-30
- Earliest claimed: 2002-04-26
- Assignees: Medtronic, Inc.
- Inventors: Warren L. Starkebaum
- Web page: https://patentgrep.com/patent/US20030204181A1

## CPC

- A61F 5/0026: {Anti-eating devices using electrical stimulation}
- A61M 5/14276: {specially adapted for implantation}
- A61M 31/002: {Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time (artificial gland structures or devices A61F2/022; intra-uterine contraceptive devices A61F6/14; tampons for introducing into the vagina A61F13/20, A61L15/00; suppositories or bougies for intra-vaginal or intra-uterine application A61K9/02; physical forms of medicinal preparations for sustained or differential drug release A61K9/20, A61K9/50)}
- A61M 5/1723: {using feedback of body parameters, e.g. blood sugar or pressure}
- A61M 2005/1405: {Patient controlled analgesia [PCA]}
- A61M 2205/3523: using telemetric means
- A61M 2205/3569: sublocal, e.g. between console and disposable
- A61M 2210/0693: Brain, cerebrum
- A61M 2210/1003: Spinal column
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}

## Abstract

Methods and systems for treating patients suffering from eating disorders, e.g. obesity, through the dispensation of a drug by an implantable infusion pump (IIP) delivering drug into the cerebral spinal fluid (CSF) at a site of the intrathecal space in amounts and at times effective to suppress the patient's appetite through interaction of the drug transported through the CSF with receptors in the brain. Delivery of a programmed drug dosage is preferably by one of time-out of programmed time(s) of day, a command received from the patient, or a trigger signal developed from a sensed GI tract signal accompanying peristalsis.

## Claims

### Claim 1

A method of delivering drug from an implantable infusion pump to receptors of the brain to therapeutically treat an eating disorder of a patient by suppressing or enhancing appetite, the method comprising the steps of:
surgically implanting an intrathecal drug infusion catheter so that a distal drug delivery portion lies in a predetermined intrathecal space site of the spinal column in cerebral spinal fluid (CSF) communication with receptors in the brain;
coupling the proximal end of the drug infusion catheter to an drug infusion pump;
implanting the drug infusion pump in the patient's body; and
operating the pump to discharge a predetermined dosage of drug into the CSF sufficient to suppress or enhance appetite through interaction of drug transported through the CSF with receptors in the brain.

### Claim 2 (depends on 1)

The method of claim 1, wherein the operating step further comprises:
providing the patient with an external medical device for communicating with the pump; and
utilizing the external medical device to communicate a command to the pump to discharge the predetermined dosage of drug into the CSF sufficient to suppress or enhance appetite through interaction with receptors in the brain.

### Claim 3 (depends on 2)

The method of claim 2, wherein the operating step further comprises:
timing out a delay time from each discharge; and
inhibiting the pump from responding to the command if the delay time has not timed out.

### Claim 4 (depends on 1)

The method of claim 1, wherein the drug is insulin acting to suppress appetite when detected by the receptors in the brain, and the operating step further comprises:
providing the patient with an external medical device for communicating with the pump; and
utilizing the external medical device to communicate a command to the pump to discharge a dosage of insulin in the range of 1×10−5-15×10−2 Units/Kg/day into the CSF sufficient to suppress appetite through interaction with receptors in the brain.

### Claim 5 (depends on 1)

The method of claim 1, wherein the drug is insulin acting to suppress appetite when detected by the receptors in the brain, and the operating step further comprises:
providing the patient with an external medical device for communicating with the pump; and
utilizing the external medical device to communicate a command to the pump to discharge the predetermined dosage of insulin into the CSF sufficient to suppress or enhance appetite through interaction with receptors in the brain.

### Claim 6 (depends on 1)

The method of claim 1, wherein the operating step further comprises:
timing out the time of day; and
operating the drug infusion pump at one or more predetermined time of day to discharge the predetermined dosage of drug into the CSF sufficient to suppress or enhance appetite through interaction with receptors in the brain.

### Claim 7 (depends on 1)

The method of claim 1, wherein the drug is insulin acting to suppress appetite when detected by the receptors in the brain, and the operating step further comprises:
timing out the time of day; and
operating the pump at one or more predetermined time of day to discharge a dosage of insulin into the CSF sufficient to suppress appetite through interaction with receptors in the brain.

### Claim 8 (depends on 1)

The method of claim 1, wherein the drug is insulin acting to suppress appetite when detected by the receptors in the brain, and the operating step further comprises:
timing out the time of day; and
operating the pump at one or more predetermined time of day to discharge a dosage of insulin in the range of 1×10−5-15×10−2 Units/Kg/day into the CSF sufficient to suppress appetite through interaction with receptors in the brain.

### Claim 9 (depends on 1)

The method of claim 1, wherein the operating step further comprises the steps of:
detecting an electrical signal of the GI tract characteristic of peristalsis; and
triggering the operation of the drug infusion pump to discharge the predetermined dosage of drug into the CSF in timed relation to the detection of the electrical signal to suppress or enhance appetite through interaction with receptors in the brain.

### Claim 10 (depends on 9)

The method of claim 9, wherein the operating step further comprises:
timing out a delay time from each discharge; and
inhibiting the pump from responding to the detection of the electrical signal of the GI tract if the delay time has not timed out.

### Claim 11 (depends on 9)

The method of claim 9, wherein the detecting step further comprises the steps of:
implanting GI tract sense electrodes at predetermined sites of the GI tract traversed by electrical signals in the GI tract wall characteristic of peristalsis;
coupling the GI tract sense electrodes to GI tract sensing circuitry for detecting the electrical signals of the GI tract characteristic of peristalsis; and
triggering the operation of the drug infusion pump to discharge the predetermined dosage of drug into the CSF in timed relation to the detection of the electrical signals to suppress or enhance appetite through interaction with receptors in the brain.

### Claim 12 (depends on 11)

The method of claim 11, wherein the GI tract sensing circuitry is located in the drug infusion pump.

### Claim 13 (depends on 9)

The method of claim 9, wherein the detecting step further comprises the steps of:
implanting GI tract sense electrodes at predetermined sites of the GI tract traversed by electrical signals in the GI tract wall characteristic of peristalsis;
coupling the GI tract sense electrodes to GI tract sensing circuitry of a GI tract monitor for detecting the signals of the GI tract characteristic of peristalsis;
implanting the GI tract monitor in the patient's body;
operating the GI tract monitor to develop a GI tract signal upon detection of the signals of the GI tract characteristic of peristalsis;
transmitting the detected electrical signals of the GI tract to the drug infusion pump; and
triggering the operation of the drug infusion pump to discharge the predetermined dosage of drug into the CSF in timed relation to the detection of the electrical signals of the GI tract to suppress or enhance appetite through interaction with receptors in the brain.

### Claim 14 (depends on 13)

The method of claim 13, wherein the drug is insulin acting to suppress appetite when detected by the receptors in the brain, and the operating step further comprises the steps of:
detecting an electrical signal of the GI tract characteristic of peristalsis; and
triggering the operation of the drug infusion pump to discharge a predetermined dosage of insulin into the CSF in timed relation to the detection of the electrical signal to suppress appetite through interaction with receptors in the brain.

### Claim 15 (depends on 9)

The method of claim 9, wherein the drug is insulin acting to suppress appetite when detected by the receptors in the brain, and the operating step further comprises the steps of:
detecting an electrical signal of the GI tract characteristic of peristalsis; and
triggering the operation of the drug infusion pump to discharge a predetermined dosage of insulin into the CSF in timed relation to the detection of the electrical signal to suppress appetite through interaction with receptors in the brain.

### Claim 16 (depends on 9)

The method of claim 9, wherein the drug is insulin acting to suppress appetite when detected by the receptors in the brain, and the operating step further comprises the steps of:
detecting an electrical signal of the GI tract characteristic of peristalsis; and
triggering the operation of the drug infusion pump to discharge a dosage of insulin in the range of 1×10−5-15×10−2 Units/Kg/day into the CSF in timed relation to the detection of the electrical signal to suppress appetite through interaction with receptors in the brain.

### Claim 17

A method of delivering drug from an implantable infusion pump to receptors of the brain to therapeutically treat an eating disorder of a patient by suppressing or enhancing appetite, the method comprising the steps of:
surgically implanting an intrathecal drug infusion catheter so that a distal drug delivery portion lies in cerebral spinal fluid (CSF) in communication with receptors in the brain;
coupling the proximal end of the drug infusion catheter to an drug infusion pump;
implanting the drug infusion pump in the patient's body;
detecting an electrical signal of the GI tract characteristic of peristalsis; and
triggering the operation of the drug infusion pump to discharge the predetermined dosage of drug into the CSF in timed relation to the detection of the electrical signal to suppress or enhance appetite through interaction with receptors in the brain.

### Claim 18 (depends on 17)

The method of claim 17, wherein the operating step further comprises:
timing out a delay time from each discharge; and
inhibiting the pump from responding to the detection of the electrical signal of the GI tract if the delay time has not timed out.

### Claim 19 (depends on 17)

The method of claim 17, wherein the detecting step further comprises the steps of:
implanting GI tract sense electrodes at predetermined sites of the GI tract traversed by electrical signals in the GI tract wall characteristic of peristalsis;
coupling the GI tract sense electrodes to GI tract sensing circuitry for detecting the electrical signals of the GI tract characteristic of peristalsis; and
triggering the operation of the drug infusion pump to discharge the predetermined dosage of drug into the CSF in timed relation to the detection of the electrical signals to suppress or enhance appetite through interaction with receptors in the brain.

### Claim 20 (depends on 19)

The method of claim 19, wherein the GI tract sensing circuitry is located in the drug infusion pump.

### Claim 21 (depends on 17)

The method of claim 17, wherein the detecting step further comprises the steps of:
implanting GI tract sense electrodes at predetermined sites of the GI tract traversed by electrical signals in the GI tract wall characteristic of peristalsis;
coupling the GI tract sense electrodes to GI tract sensing circuitry of a GI tract monitor for detecting the signals of the GI tract characteristic of peristalsis;
implanting the GI tract monitor in the patient's body;
operating the GI tract monitor to develop a GI tract signal upon detection of the signals of the GI tract characteristic of peristalsis;
transmitting the detected electrical signals of the GI tract to the drug infusion pump; and
triggering the operation of the drug infusion pump to discharge the predetermined dosage of drug into the CSF in timed relation to the detection of the electrical signals of the GI tract to suppress or enhance appetite through interaction with receptors in the brain.

### Claim 22 (depends on 17)

The method of claim 17, wherein the drug is insulin acting to suppress appetite when detected by the receptors in the brain, and the triggering step further comprises triggering the operation of the drug infusion pump to discharge a predetermined dosage of insulin into the CSF in timed relation to the detection of the electrical signal to suppress appetite through interaction with receptors in the brain.

### Claim 23 (depends on 17)

The method of claim 17, wherein the drug is insulin acting to suppress appetite when detected by the receptors in the brain, and the triggering step further comprises triggering the operation of the drug infusion pump to discharge a predetermined dosage of insulin in the range of 1×10−5-15×10−2 Units/Kg/day into the CSF in timed relation to the detection of the electrical signal to suppress appetite through interaction with receptors in the brain.

### Claim 24

A system comprising an implantable infusion pump for delivering drug to receptors of the brain to therapeutically treat an eating disorder of a patient by suppressing or enhancing the patient's appetite, the system comprising:
an intrathecal drug infusion catheter having catheter lumen extending from a catheter proximal end and a distal drug infusion portion adapted to be implanted so that the distal drug delivery portion lies in a predetermined intrathecal space site of the spinal column in cerebral spinal fluid (CSF) in communication with receptors in the brain;
a drug infusion pump comprising an drug reservoir, a roller pump and infusion discharge control circuitry adapted to be implanted in the patient and coupled to a proximal end of the drug infusion catheter, the infusion discharge control circuitry providing an infusion discharge control signal; and
means responsive to an infusion discharge control signal of the infusion discharge control circuitry for initiating operation of the roller pump to discharge a predetermined dosage of drug into the cerebral spinal fluid (CSF) sufficient to suppress or enhance appetite through interaction of drug transported through the CSF with receptors in the brain.

### Claim 25 (depends on 24)

The system of claim 24, further comprising an external medical device operable by the patient or a medical care provider to generate an drug discharge command, and the drug infusion discharge control circuitry comprises:
means for receiving and responding to the drug discharge command from the external medical device to develop the infusion discharge control signal; and
means for timing out a delay time from each discharge; and
means for inhibiting the pump from responding to the command if the delay time has not timed out.

### Claim 26 (depends on 24)

The system of claim 24, further comprising an external medical device operable by the patient or a medical care provider to generate an drug discharge command, and the drug infusion discharge control circuitry comprises means for receiving and responding to the drug discharge command from the external medical device to develop the infusion discharge control signal.

### Claim 27 (depends on 26)

The system of claim 26, wherein the drug is insulin acting to suppress appetite when detected by the receptors in the brain, and the triggering step further comprises triggering the operation of the drug infusion pump to discharge a predetermined dosage of insulin into the CSF in timed relation to the detection of the electrical signal to suppress appetite through interaction with receptors in the brain.

### Claim 28 (depends on 26)

The system of claim 26, wherein the drug is insulin acting to suppress appetite when detected by the receptors in the brain, and the triggering step further comprises triggering the operation of the drug infusion pump to discharge a predetermined dosage of insulin in the range of 1×10−5-15×10−2 Units/Kg/day into the CSF in timed relation to the detection of the electrical signal to suppress appetite through interaction with receptors in the brain.

### Claim 29 (depends on 24)

The system of claim 24, wherein the drug infusion discharge control circuitry comprises:
means for timing out the time of day; and
means for operating the drug infusion pump at one or more predetermined time of day to discharge the predetermined dosage of drug into the CSF sufficient to suppress or enhance appetite through interaction with receptors in the brain.

### Claim 30 (depends on 29)

The system of claim 29, wherein the drug is insulin acting to suppress appetite when detected by the receptors in the brain, and the triggering step further comprises triggering the operation of the drug infusion pump to discharge a predetermined dosage of insulin into the CSF in timed relation to the detection of the electrical signal to suppress appetite through interaction with receptors in the brain.

### Claim 31 (depends on 29)

The system of claim 29, wherein the drug is insulin acting to suppress appetite when detected by the receptors in the brain, and the triggering step further comprises triggering the operation of the drug infusion pump to discharge a predetermined dosage of insulin in the range of 1×10−5-15×10−2 Units/Kg/day into the CSF in timed relation to the detection of the electrical signal to suppress appetite through interaction with receptors in the brain.

### Claim 32 (depends on 24)

The system of claim 24, wherein the drug infusion discharge control circuitry comprises:
means for detecting an electrical signal of the GI tract characteristic of peristalsis; and
means for triggering the operation of the drug infusion pump to discharge the predetermined dosage of drug into the CSF in timed relation to the detection of the electrical signal to suppress or enhance appetite through interaction with receptors in the brain.

### Claim 33 (depends on 32)

The system of claim 32, wherein the drug infusion discharge control circuitry comprises:
means for timing out a delay time from each discharge; and
means for inhibiting the pump from responding to the detection of the electrical signal of the GI tract if the delay time has not timed out.

### Claim 34 (depends on 24)

The system of claim 24, further comprising:
GI tract sense electrodes adapted to be implanted at predetermined sites of the GI tract traversed by electrical signals in the GI tract wall characteristic of peristalsis; and
GI tract sensing circuitry coupled with the GI tract sense electrodes for detecting the electrical signals of the GI tract characteristic of peristalsis; and
wherein the drug infusion discharge control circuitry comprises means for triggering the operation of the drug infusion pump to discharge the predetermined dosage of drug into the CSF in timed relation to the detection of the electrical signals to suppress or enhance appetite through interaction with receptors in the brain.

### Claim 35 (depends on 34)

The system of claim 34, wherein the GI tract sensing circuitry is located in the drug infusion pump.

### Claim 36 (depends on 24)

The system of claim 24, further comprising:
GI tract leads bearing a sense electrodes adapted to be implanted at predetermined sites of the GI tract traversed by electrical signals in the GI tract wall characteristic of peristalsis; and
a GI tract monitor adapted to be implanted in the patient's body and coupled to the GI tract leads sense electrodes and further comprising:
sense means for detecting the signals of the GI tract characteristic of peristalsis;
means for developing a GI tract signal upon detection of the signals of the GI tract characteristic of peristalsis; and
means for transmitting the detected electrical signals of the GI tract to the drug infusion pump; and wherein:
the drug infusion discharge control circuitry comprises means for receiving the transmitted electrical signals of the GI tract and for triggering the operation of the drug infusion pump to discharge the predetermined dosage of drug into the CSF in timed relation to the detection of the electrical signals of the GI tract to suppress or enhance appetite through interaction with receptors in the brain.

### Claim 37 (depends on 24)

The system of claim 24, wherein the drug is insulin acting to suppress appetite when detected by the receptors in the brain, and the operating step further comprises:
means for detecting an electrical signal of the GI tract characteristic of peristalsis; and
means for triggering the operation of the drug infusion pump to discharge a predetermined dosage of insulin into the CSF in timed relation to the detection of the electrical signal to suppress appetite through interaction with receptors in the brain.

### Claim 38 (depends on 24)

The system of claim 24, wherein the drug is insulin acting to suppress appetite when detected by the receptors in the brain, and the operating step further comprises:
means for detecting an electrical signal of the GI tract characteristic of peristalsis; and
means for triggering the operation of the drug infusion pump to discharge a dosage of insulin in the range of 1×10−5-15×10−2 Units/Kg/day into the CSF in timed relation to the detection of the electrical signal to suppress appetite through interaction with receptors in the brain.

### Claim 39

A system delivering drug from an implantable infusion pump to receptors of the brain to therapeutically treat an eating disorder of a patient by suppressing or enhancing appetite comprising:
a drug infusion catheter having catheter lumen extending from a catheter proximal end and a distal drug infusion portion adapted to be implanted so that the distal drug delivery portion lies in cerebral spinal fluid (CSF) in communication with receptors in the brain;
a drug infusion pump comprising an drug reservoir, a roller pump, and infusion discharge control circuitry adapted to be implanted in the patient and coupled to a proximal end of the drug infusion catheter;
means for detecting an electrical signal of the GI tract characteristic of peristalsis; and
means for triggering the operation of the drug infusion pump to discharge the predetermined dosage of drug into the CSF in timed relation to the detection of the electrical signal to suppress or enhance appetite through interaction with receptors in the brain.

### Claim 40 (depends on 39)

The system of claim 39, further comprising:
means for timing out a delay time from each discharge; and
means for inhibiting the pump from responding to the detection of the electrical signal of the GI tract if the delay time has not timed out.

### Claim 41 (depends on 39)

The system of claim 39, wherein the detecting means further comprises:
GI tract sensing circuitry for detecting the electrical signals of the GI tract characteristic of peristalsis
GI tract sense electrodes adapted to be implanted at predetermined sites of the GI tract traversed by electrical signals in the GI tract wall characteristic of peristalsis; and
GI tract leads coupling the GI tract sense electrodes to the GI tract sensing circuitry.

### Claim 42 (depends on 41)

The system of claim 41, wherein the GI tract sensing circuitry is located in the drug infusion pump.

### Claim 43 (depends on 39)

The system of claim 39, wherein the detecting means further comprises:
GI tract leads having GI tract sense electrodes adapted to be implanted at predetermined sites of the GI tract traversed by electrical signals in the GI tract wall characteristic of peristalsis; and
a GI tract monitor adapted to be implanted in the patient's body comprising:
GI tract sensing circuitry coup[led to the GI tract leads for detecting the electrical signals of the GI tract characteristic of peristalsis; and
means for transmitting the detected electrical signals of the GI tract to the drug infusion pump.

### Claim 44 (depends on 39)

The system of claim 39, wherein the drug is insulin acting to suppress appetite when detected by the receptors in the brain, and the triggering means further comprises means for triggering the operation of the drug infusion pump to discharge a predetermined dosage of insulin into the CSF in timed relation to the detection of the electrical signal to suppress appetite through interaction with receptors in the brain.

### Claim 45 (depends on 39)

The system of claim 39, wherein the drug is insulin acting to suppress appetite when detected by the receptors in the brain, and the triggering means further comprises means for triggering the operation of the drug infusion pump to discharge a predetermined dosage of insulin in the range of 1×10−5-15×10−2 Units/Kg/day into the CSF in timed relation to the detection of the electrical signal to suppress appetite through interaction with receptors in the brain.
